American Fusion Secures $793K in Prepaid Warrant Financing, Reduces Authorized Shares, and Pursues Uplisting

summarizeSummary

American Fusion, Inc. announced it secured $793,000 through a prepaid warrant facility with a fixed exercise price of $0.05 per share, with up to $2.2 million more available, alongside a significant reduction in authorized common shares and steps towards becoming a fully reporting company.

check_boxKey Events · Financing and Capital Events · AMFN

• Secured Prepaid Warrant Financing

  American Fusion entered into a Master Prepaid Common Stock Purchase Warrant Agreement, securing approximately $793,000 in financing to date. The facility allows for up to $3,000,000 in total funding, with $2,207,000 remaining available.

• Authorized Share Reduction

  The company formally reduced its authorized common shares from 3,000,000,000 to 1,800,000,000. This follows a previous cancellation of 1.683 billion shares, aligning the capital structure with current needs and reducing excess capacity.

• Fixed-Price Warrants Issued

  The warrants issued under the facility are exercisable at a fixed price of $0.05 per share, with the full purchase price prepaid by the investor. The company highlighted that these terms avoid variable rate or floating conversion features common in other OTC financings.

• Steps Towards Uplisting and Transparency

  American Fusion is pursuing a Rule 15c2-11 quotation to improve trading visibility and liquidity. The company also anticipates its Form 10 registration statement to become effective around May 15, 2026, making it a fully reporting company with the SEC.

auto_awesomeAnalysis · AMFN · Energy & Transportation

This filing details a multi-faceted strategic update for American Fusion. The company has secured crucial financing of $793,000 via prepaid warrants, with the potential for an additional $2.2 million, providing capital for operations and growth. While the warrants are dilutive and exercisable at a price below the current market, the fixed terms are presented as more favorable than typical variable-rate financing for OTC companies. Concurrently, the company has reduced its authorized share count from 3 billion to 1.8 billion, a positive governance move that limits future dilution potential. Furthermore, steps towards becoming a fully reporting company and improving trading visibility signal a commitment to transparency and market uplisting. Investors should monitor the utilization of the remaining facility and the progress of its uplisting efforts.